Balixafortide (POL-6326), a synthetic cyclopeptide derived from polyphemusin, is a novel, potent and orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4, IC 50=10 nM) with anticancer activity.

LY2510924 (LY-2510924), a small cyclic peptide, is a novel, potent and selective CXCR4 (CXC chemokine receptor 4) antagonist with potential anticancer and anti-inflammatory activity.

LIT-927 (LIT927 ) is a novel potent, locally and orally bioactive neutraligand for the chemokine CXCL12 with anti-inflammatory and anticancer activity.  

Mavorixafor (AMD-070; AMD11070, AMD070, X4P-001) is an orally bioavailable CXCR4 antagonist with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, it inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs.

MSX-122 is a novel, potent and orally bioavailable inhibitor/partial antagonist of CXCR4 which inhibits CXCR4/CXCL12 actions with an IC50 of 10 nM.

PS372424 (PS-372424) HCl is a novel and potent agonist of CXCR3 with anti-inflammatory activity.

NUCC-390 diHCl is a novel, potent, and specific small-molecule CXCR4 receptor agonist.

SB225002 (SB 225002; SB-225002) is a novel, potent, and selective non-peptide antagonist of chemokine receptor CXCR2 with potential anti-inflammatory activity.

SCH-563705 (SCH563705) is a novel potent and orally bioactive antagonist of CXCR2 and CXCR1 with anti-Inflammatory and immunomodulatory activity.

SRT3190 (SRT-3190) is a potent and selective antagonist of CXCR2 (C-X-C chemokine receptor type 2) and an activator of SIRT1 with anti-Inflammatory and immunomodulatory activity.